Skip to main content

DICE Therapeutics, Inc.

DICEDelisted Aug 9, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001645569

DICE Therapeutics, Inc. was delisted on Aug 9, 2023; its insiders filed their last Form 4 on Aug 9, 2023; 160 institutions reported holding it in 13F filings for Q2 2023, worth $2.12B in total; Fairfax Financial was the only superinvestor holding it.

Holders of 5% or more of DICE

Holders whose latest Schedule 13D or 13G filing reports 5% or more of DICE Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of DICE Therapeutics, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

Schedule 13D and 13G filings on DICE Therapeutics, Inc., newest first.

Schedule 13D and 13G filings on DICE
Filed (ET)FilerFormStakeChangeEvent dateFiling
Sep 28, 2021Northpond Ventures, LP13DOld format–New–SEC
Sep 27, 2021Sands Capital Life Sciences Pulse Fund II, L.P.13DOld format–New–SEC
Sep 27, 2021Ra Capital Management, L.P.13DOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell DICE Therapeutics, Inc. shares.

No Form 144 notices for DICE Therapeutics, Inc. are on file.